Update shared on 28 Nov 2025
Analysts have maintained their fair value estimate for Galenica at CHF 86.17. They cite modest increases in projected revenue growth and profit margin as key supporting factors.
What's in the News
- Galenica AG has issued earnings guidance for 2025, forecasting sales growth between 4% and 6% and an EBIT increase of 10% to 12% (Key Developments).
- The company is piloting a new pharmacy concept at Amavita in Zurich's Glattzentrum, focusing on enhanced consultations and customer experience (Key Developments).
- The redesigned pharmacy features express checkouts, private rooms for discreet consultations, and semi-private consultation areas where customers can interact with specialists using digital tools (Key Developments).
- Galenica continues targeted investments in integrating digital and in-store services to meet evolving customer needs and expectations (Key Developments).
Valuation Changes
- Fair Value Estimate remained steady at CHF 86.17, with no change from the previous assessment.
- Discount Rate held constant at 3.86%, indicating unchanged risk assumptions in the valuation model.
- Revenue Growth forecast has risen slightly. It is now projected at 4.34%, up from 4.21% previously.
- Profit Margin expectation has increased marginally to 4.73%, compared to the earlier estimate of 4.72%.
- Future Price/Earnings (P/E) Ratio is forecast to fall slightly to 22.30x, down from 22.44x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.